Hormonal content and potency of oral contraceptives and breast cancer risk among young women

British Journal of Cancer

Volumn 88, Issue 1, 2003, Pages 50-57

  Althuis, M D ^a   Brogan, D R ^b   Coates, R J ^c   Daling, J R ^d   Gammon, M D ^e   Malone, K E ^d   Schoenberg, J B ^f   Brinton, L A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f New Jersey State Dept Hlth Sr S   (United States)

Author keywords

Breast cancer; Formulation; Oestrogen; Oral contraceptives; Progestin

Indexed keywords

ETHINYLESTRADIOL; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

AGE; ARTICLE; BREAST CANCER; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG FORMULATION; DRUG POTENCY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; FEMALE; HORMONES; HUMANS; MIDDLE AGED; RISK FACTORS; STATISTICS;

EID: 0037434427     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600691     Document Type: Article

References (38)

1. Boonstra H, Duran V, Northington GV, Blumenthal P, Dominguez L, Pies C (2000) The 'boom and bust phenomenon': the hopes, dreams, and broken promises of the contraceptive revolution. Contraception 61: 9-25
2. Breslow NE, Day NE (1980) The analysis of case-control studies. In Statistical Methods in Cancer Research - Volume 1, pp 5-338. IARC Scientific Publications
3. Brinton LA, Daling JR, Liff JM, Schoenberg JB, Malone KE, Stanford JL, Coates RJ, Gammon MD, Hanson L, Hoover RN (1995) Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst 87: 827-835
4. Brody SA, Turkes A, Goldzieher JW (1989) Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are 'low-dose' pills really lower? Contraception 40: 269-284
5. Burkman RT (2001) Oral contraceptives: current status. Clin Obstet Gynecol 44: 62-72
6. Collaborative Group on Hormonal Factors in Breast Cancer (1996a) Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727
7. Collaborative Group on Hormonal Factors in Breast Cancer (1996b) Breast cancer and hormonal contraceptives: further results. Contraception 54: 1S-106S
8. Collins DC (1994) Sex hormone receptor binding, progestin selectivity, and the new oral contraceptives. Am J Obstet Gynecol 170: 1508-1513
9. Coulter A, Vessey M, McPherson K, Crossley B (1986) The ability of women to recall their oral contraceptive histories. Contraception 33: 127-137
10. Dorflinger LJ (1985) Relative potency of progestins used in oral contraceptives. Contraception 31: 557-570
11. Harlow SD, Linet MS. (1989) Agreement between questionnaire data and medical records. The evidence for accuracy of recall. Am J Epidemiol 129: 233-248
12. Isaksson E, von Schoultz E, Odlind V, Soderqvist G, Csemiczky G, Carlstrom K, Skoog L, von Schoultz B (2001) Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 65: 163-169
13. Jeng MH, Parker CJ, Jordan VC (1992) Estrogenic potential of progestins in oral contraceptives to stimulate human breast cancer cell proliferation. Cancer Res 52: 6539-6546
14. Jick SS, Walker AM, Stergachis A, Jick H (1989) Oral contraceptives and breast cancer. Br J Cancer 59: 618-621
15. Madigan MP, Troisi R, Potischman N, Brogan D, Gammon MD, Malone KE, Brinton LA (2000) Characteristics of respondents and non-respondents from a case-control study of breast cancer in younger women. Int J Epidemiol 29: 793-798
16. Marchbanks PA, McDonald JA, Wilson HG, Folger SG, Mandel MG, Daling JR, Bernstein L, Malone KE, Ursin G, Strom BL, Norman SA, Weiss LK (2002) Oral contraceptives and risk of breast cancer. N Engl J Med 346: 2025-2032
17. McPherson K, Vessey MP, Neil A, Doll R, Jones L, Roberts M (1987) Early oral contraceptive use and breast cancer: results of another case-control study. Br J Cancer 56: 653-660
18. Meirik O, Lund E, Adami HO, Bergstrom R, Christoffersen T, Bergsjo P. (1986) Oral contraceptive use and breast cancer in young women. A joint national case-control study in Sweden and Norway. Lancet 2: 650-654
19. Mishell Jr DR (1989) The pharmacologic and metabolic effects of oral contraceptives. Int J Fertil 34 (Suppl): 21-26
20. Paul C, Skegg DC, Spears GF (1990) Oral contraceptives and risk of breast cancer. Int J Cancer 46: 366-373
21. Phillips A, Hahn DW, Klimek S, McGuire JL (1987) A comparison of the potencies and activities of progestogens used in contraceptives. Contraception 36: 181-192
22. Piccinino LJ, Mosher WD (1998) Trends in contraceptive use in the United States: 1982-1995. Fam Plann Perspect 30: 4-10, 46
23. Pike MC, Henderson BE, Krailo MD, Duke A, Roy S (1983) Breast cancer in young women and use of oral contraceptives: possible modifying effect of formulation and age at use. Lancet 2: 926-930
24. Piper JM, Kennedy DL (1987) Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol 16: 215-221
25. Primic-Zakelj M, Evstifeeva T, Ravnihar B, Boyle P (1995) Breast-cancer risk and oral contraceptive use in Slovenian women aged 25 to 54. Int J Cancer 62: 414-420
26. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis Jr JL, Strom BL, Harlap S, Shapiro S (1994) A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139: 654-661
27. Rosenblatt KA, Thomas DB, Noonan EA (1992) High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effect. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 28A: 1872-1876
28. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC (2002) Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 94: 32-38
29. Stubblefield PG (1986) Biological activity of oral contraceptives. Int J Fertil 31 SU [UPDATE]: 4-12
30. UK National Case-Control Study Group (1989) Oral contraceptive use and breast cancer risk in young women. Lancet 1: 973-982
31. Ursin G, Ross RK, Sullivan-Halley J, Hanisch R, Henderson B, Bernstein L (1998) Use of oral contraceptives and risk of breast cancer in young women. Breast Cancer Res Treat 50: 175-184
32. Vessey M, Baron J, Doll R, McPherson K, Yeates D (1983) Oral contraceptives and breast cancer: final report of an epidemiological study. Br J Cancer 47: 455-462
33. Vessey MP, McPherson K, Villard-Mackintosh L, Yeates D (1989) Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 59: 613-617
34. Weinstein AL, Mahoney MC, Nasca PC, Leske MC, Varma AO (1991) Breast cancer risk and oral contraceptive use: results from a large case-control study. Epidemiology 2: 353-358
35. White E, Malone KE, Weiss NS, Daling JR (1994) Breast cancer among young U.S. women in relation to oral contraceptive use. J Natl Cancer Inst 86: 505-514
36. Wilson JD, Foster DW, Kronenberg HM, Larson PR (1998) Hormone and hormone action. In Williams Textbook of Endocrinology, Wilson JD et al (eds) pp 1-163. Philadelphia: W.B. Saunders Company
37. Wingo PA, Lee NC, Ory HW, Beral V, Peterson HB, Rhodes P (1993) Age-specific differences in the relationship between oral contraceptive use and breast cancer. Cancer 71: 1506-1517
38. Wolters A (1997) Sex hormones. In Drug Facts and Comparisons, pp 410-510. St Louis: Kluwer Company